Table 3.
Comparison of signal intensity between grades and European Neuroendocrine Society tumor-nodes-metastases stages
| Feature |
Grade |
ENETS TNM stage1 |
||||||
| Total | G12 | G2-32 | P value | Total | I/II2 | III/IV2 | P value | |
| T1w | 0.395 | 0.659 | ||||||
| Hypointense | 45 | 27 (60) | 18 (40) | 42 | 22 (52.4) | 20 (47.6) | ||
| Isointense | 4 | 1 (25) | 3 (75) | 4 | 1 (25) | 3 (75) | ||
| Hyperintense | 6 | 3 (50) | 3 (50) | 5 | 2 (40) | 3 (60) | ||
| fsT1w | 0.836 | 0.900 | ||||||
| Hypointense | 39 | 23 (59) | 16 (41) | 37 | 19 (51.4) | 18 (48.6) | ||
| Isointense | 9 | 5 (55.6) | 4 (44.4) | 8 | 3 (37.5) | 5 (62.5) | ||
| Hyperintense | 7 | 3 (42.9) | 4 (57.1) | 6 | 3 (50) | 3 (50) | ||
| T2w | 0.937 | 0.274 | ||||||
| Hypointense | 16 | 9 (56.3) | 7 (43.2) | 16 | 8 (50) | 8 (50) | ||
| Isointense | 12 | 6 (50) | 6 (50) | 11 | 3 (27.3) | 8 (72.7) | ||
| Hyperintense | 27 | 16 (59.3) | 11 (40.7) | 24 | 14 (58.3) | 10 (41.7) | ||
| fsT2w | 1.000 | 0.318 | ||||||
| Hypointense | 13 | 7 (53.8) | 6 (46.2) | 13 | 5 (38.5) | 8 (61.5) | ||
| Isointense | 11 | 6 (54.5) | 5 (45.5) | 9 | 3 (33.3) | 6 (66.7) | ||
| Hyperintense | 31 | 18 (58.1) | 13 (41.9) | 29 | 17 (58.6) | 12 (41.4) | ||
| Fluid areas | 0.279 | 0.464 | ||||||
| Present | 15 | 7 (46.7) | 8 (53.3) | 15 | 8 (53.3) | 7 (46.7) | ||
| Absent | 40 | 24 (60) | 16 (40) | 38 | 17 (47.2) | 19 (52.8) | ||
| Arterial | 0.089 | 0.055 | ||||||
| Hypointense | 13 | 4 (30.8) | 9 (69.2) | 12 | 3 (25) | 9 (75) | ||
| Isointense | 11 | 8 (72.7) | 3 (27.3) | 9 | 3 (33.3) | 6 (66.7) | ||
| Hyperintense | 31 | 19 (61.3) | 12 (38.7) | 30 | 19 (63.3) | 11 (36.7) | ||
| Portal | 1.000 | 0.933 | ||||||
| Hypointense | 14 | 8 (57.1) | 6 (42.9) | 14 | 6 (42.9) | 8 (57.1) | ||
| Isointense | 13 | 7 (53.8) | 6 (46.2) | 12 | 6 (50) | 6 (50) | ||
| Hyperintense | 28 | 16 (57.1) | 12 (42.9) | 25 | 13 (52) | 12 (48) | ||
| Delayed | 0.441 | 0.340 | ||||||
| Hypointense | 12 | 6 (50) | 6 (50) | 11 | 4 (36.4) | 7 (63.6) | ||
| Isointense | 19 | 9 (47.4) | 10 (52.6) | 17 | 7 (41.2) | 10 (58.8) | ||
| Hyperintense | 24 | 16 (66.7) | 8 (33.3) | 23 | 14 (60.9) | 9 (39.1) | ||
| Enhancement | 0.006 | 0.163 | ||||||
| Heterogeneous | 25 | 9 (36) | 16 (64) | 25 | 10 (40) | 15 (60) | ||
| Homogeneous | 30 | 22 (73.3) | 8 (26.7) | 26 | 15 (57.7) | 11 (42.3) | ||
1
Four lesions were excluded from this analysis (minimally invasive surgery without lymphadenectomy);
2
Number of cases/cases in row. ENETS: European Neuroendocrine Society; TNM: Tumor-nodes-metastases.